Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer
Sietske C. van Nassau(University Medical Center Utrecht), Lieke H. J. Simkens, Erica H A Groen, Dirkje W. Sommeijer, Marinde J. G. Bond(Utrecht University), Louise J. M. Alferink, Milou S Keusters, Ankie M.T. van der Velden, Sadaf Oliai Araghi, Ilva Scheerman(University Medical Center Utrecht), Mathijs P. Hendriks(Northwest Hospital), Carolien Haazer, Hester van Cruijssen, Frank J. Jeurissen(Medisch Centrum Haaglanden), Nikki F T Henckens, Leon van Hout, Brigitte C.M. Haberkorn(Maasstad Ziekenhuis), Arie J. Verschoor, Mark P.S. Sie, Karin E M de Nijs, V.E.P.P. Lemmens(Erasmus MC), Tineke E. Buffart(Amsterdam UMC Location Vrije Universiteit Amsterdam), Theo van Voorthuizen, Peter Nieboer, Jesper van Breeschoten(Amsterdam University Medical Centers), Leonie J. Mekenkamp(Dutch Colorectal Cancer Group), Liselot B. Valkenburg-van Iersel(Maastricht University), Miriam Koopman(Radboud University Nijmegen), Guus M. Bol(Johns Hopkins University), Arthur D van Leeuwen, Rob Kessels(The Netherlands Cancer Institute), Els J E Wink-van Gestel, Marly van Cranenbroek, Lonneke W. Kessels, Zonne L. M. Hofman, Judith J Zwartjens, Frederiek Terheggen, Henk M.W. Verheul(Erasmus MC), Mirte Mayke Streppel(Johns Hopkins University), Merel Pieters, P Werner, Wendy E C J Heuts, Maartje Los(St. Antonius Ziekenhuis), Felix E. de Jongh, Hans‐Martin Otten, Ronald Hoekstra, Natascha A. J. B. Peters, Loes M Latten-Jansen, Geert‐Jan Creemers, Lieke L H van Huis-Tanja
Cited by 10
Related Papers
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
|British Journal of Cancer|2009|518
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
|Nature reviews. Cancer|2007|502
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
|Angiogenesis|2009|488